Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis

• Published in: International journal of radiation oncology, biology, physics Vol. 66; no. 5; pp. 1584 - 1589
• Main Authors: Suzuki, Minoru, Sakurai, Yoshinori, Masunaga, Shinichiro, Kinashi, Yuko, Nagata, Kenji, Maruhashi, Akira, Ono, Koji
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2006
• Subjects: BORON; Boron Compounds - therapeutic use; Boron neutron capture therapy; Boron Neutron Capture Therapy - methods; CARCINOMAS; CLINICAL TRIALS; Feasibility Studies; Humans; Lung; LUNGS; Malignant pleural mesothelioma; Mesothelioma - radiotherapy; NEUTRON CAPTURE THERAPY; PATIENTS; PLANNING; Pleural Neoplasms - radiotherapy; RADIATION DOSE DISTRIBUTIONS; RADIATION DOSES; RADIOLOGY AND NUCLEAR MEDICINE; Radiotherapy Dosage; SIMULATION; Boron neutron capture therapy; Malignant pleural mesothelioma
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2006.08.026

Purpose: To investigate the feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma (MPM) from a viewpoint of dose distribution analysis using Simulation Environment for Radiotherapy Applications (SERA), a currently available BNCT treatment planning system. Methods and Materials: The BNCT treatment plans were constructed for 3 patients with MPM using the SERA system, with 2 opposed anterior–posterior beams. The 10B concentrations in the tumor and normal lung in this study were assumed to be 84 and 24 ppm, respectively, and were derived from data observed in clinical trials. The maximum, mean, and minimum doses to the tumors and the normal lung were assessed for each plan. The doses delivered to 5% and 95% of the tumor volume, D 05 and D 95, were adopted as the representative dose for the maximum and minimum dose, respectively. Results: When the D 05 to the normal ipsilateral lung was 5 Gy-Eq, the D 95 and mean doses delivered to the normal lung were 2.2–3.6 and 3.5–4.2 Gy-Eq, respectively. The mean doses delivered to the tumors were 22.4–27.2 Gy-Eq. The D 05 and D 95 doses to the tumors were 9.6–15.0 and 31.5–39.5 Gy-Eq, respectively. Conclusions: From a viewpoint of the dose–distribution analysis, BNCT has the possibility to be a promising treatment for MPM patients who are inoperable because of age and other medical illnesses.